Last edition
News about Global Pharma
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Global Pharma | 05/09/2025 | By Dineshwori | 541
Syantra, Inc., a cancer diagnostics innovator, has launched a new therapeutic division aimed at developing first-in-class immuno-oncology therapies to reprogram tumour-affected immune cells and restore anti-cancer immunity.
Global Pharma | 05/09/2025 | By Mrinmoy Dey | 144
Zydus and Synthon Sign Exclusive Licensing and Supply Agreement for Ozanimod Capsules for US Market
Zydus Lifesciences’ subsidiary Zydus Lifesciences Global FZE has signed an exclusive licensing and supply deal with Synthon BV to commercialise generic Ozanimod Capsules (ZEPOSIA) in the US market.
Global Pharma | 05/09/2025 | By Mrinmoy Dey | 230
NAYA Therapeutics Partners with Atley Solutions on Astatine-211 Radio Pharmaceuticals
NAYA Therapeutics will leverage Atley’s clinical manufacturing network and establish additional GMP sites using the Atley C100 for the final clinical-dose manufacturing of 211 At Targeted Alpha Therapies.
Global Pharma | 04/09/2025 | By Dineshwori | 479
Cayman Chemical, Curapath Join Forces to Expand Access to PEG-Free Shielding Lipids for LNPs
Cayman Chemical and Curapath have partnered to make PEG-free shielding lipids available to researchers advancing LNPs for non-viral drug delivery, gene therapy, mRNA vaccines, and biologic therapies.
Global Pharma | 04/09/2025 | By Mrinmoy Dey | 295
Lupin Secures US FDA Approval for Risperidone Long-Acting Injectable
Lupin has received US FDA approval for its Risperidone extended-release injectable suspension, marking the first product from its Nanomi long-acting injectables platform with 180-day CGT exclusivity.
Global Pharma | 03/09/2025 | By Mrinmoy Dey | 184
Quotient Sciences and CPI to Form JV to Accelerate RNA Drug Development
Quotient Sciences and UK innovation centre CPI have signed an MoU to form a joint venture that will accelerate the development of RNA-based therapies through an integrated, end-to-end platform.
Global Pharma | 03/09/2025 | By Mrinmoy Dey | 290
SeqOne Strengthens UK Presence with Acquisition of Congenica
The acquisition of UK genomics leader Congenica strengthens SeqOne’s market position and global footprint, servicing over 160 labs in more than 30 countries.
Global Pharma | 03/09/2025 | By Dineshwori | 174
LOTTE BIOLOGICS Enters Contract Manufacturing Partnership with US Biopharma
South Korea’s LOTTE BIOLOGICS has signed a late-stage to commercial contract manufacturing agreement with a US-based global biopharmaceutical company.
Global Pharma | 02/09/2025 | By Dineshwori | 476
Servier and IDEAYA Biosciences have entered into an exclusive license agreement to globally develop and commercialise darovasertib, a potential first-in-class therapy for uveal melanoma, with Servier taking rights outside the US and IDEAYA retaining US rights.
Global Pharma | 02/09/2025 | By Mrinmoy Dey | 263
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy